Alliance for Pandemic Preparedness

June 15, 2021

Safety and Immunogenicity of a Third Dose of SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients: A Case Series

Category:

Topic:

Keywords (Tags): ,

  • In solid organ transplant recipients, a third dose of a COVID-19 vaccine was not able to elicit detectable anti-SARS-CoV-2 antibody responses in 53% of participants in a cohort study (n=30). Prior to receiving the third dose, 80% of patients did not have detectable antibody responses. All patients were fully vaccinated with mRNA vaccines (57% Pfizer-BioNTech, 43% Moderna), and received the third dose after a median of 67 days (50% Johnson & Johnson-Janssen, 30% Moderna, 20% Pfizer-BioNTech). Participants were assessed for an antibody response after a median of 14 days after the third vaccination.

Werbel et al. (June 15, 2021). Safety and Immunogenicity of a Third Dose of SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients: A Case Series. Annals of Internal Medicine. https://doi.org/10.7326/L21-0282